Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.
Treadwell Therapeutics has raised $91.0M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Treadwell Therapeutics's investors include Sino Biopharmaceutical, Adrian Cheng, 3W Fund Management, TIO Bioventures, Prosperous Alliance Investments.
Treadwell Therapeutics is headquartered in New York, United States.
Treadwell Therapeutics is a clinical-stage oncology company that develops medicines to address unmet needs in patients with cancer.
Treadwell Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Treadwell Therapeutics — Funding & Investors." VCBacked, November 18, 2021, https://www.vcbacked.co/company/treadwell-therapeutics. Accessed August 14, 2026.
VCBacked. (2021). Treadwell Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/treadwell-therapeutics
{{cite web |title=Treadwell Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/treadwell-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated